Vanda Pharmaceuticals, Inc.

NASDAQ: VNDA
$19.49
+$0.11 (+0.6%)
Closing price June 16, 2021
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Amazon, Caterpillar, Disney, EA, Target and more.
Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
Vanda Pharma shares dropped early to start out the week after the frim announced that it received a Complete Response Letter from the FDA.
The top analyst upgrades, downgrades and initiations seen on Thursday included Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital and Whiting Petroleum.
The top analyst upgrades, downgrades and initiations seen on Thursday included AT&T, Caterpillar, Dollar General, Electronic Arts, Etsy, Facebook, Spirit Airlines, Tesla and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Apple, Apptio, Cheniere Energy, First Solar, Kratos Defense & Security Solutions, Smartsheet,...
Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include American Express, Encana, Petrobras, Raytheon, Tesla and Walgreens.